Nebenwirkungen · Pyzchiva
Pyzchiva 45 mg solution for injection Pyzchiva 45 mg solution for injection in pre-filled syringe Pyzchiva 90 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 28
HOS-152017 · Präparat HOS-100665
Paediatric patients weighing at least 40 kg with Crohn’s disease The safety of ustekinumab has been studied in one phase 1 and one phase 3 study of paediatric patients with moderately to severely active Crohn’s disease up to week 240 and week 52, respectively. In general, the safety profile in this cohort (n = 71) was similar to that seen in previous studies in adults with Crohn’s disease.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T14:40:00Z · SHA-256 24f42a13e263361e45daf03240bd1f30ff701ef234e4b135f72f1f3a44cecfae · Passage 30a8e43f07c1a5ac796534b7653c9cfd41e300fb7ce16d7f22d56c0f7353a290 · Zeichen 8712–9104 im Abschnitt